162 related articles for article (PubMed ID: 30502508)
1. Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis.
Hirano I; Dellon ES; Collins MH; Williams J; Lan L; Katzka DA
Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2126-2128.e1. PubMed ID: 30502508
[TBL] [Abstract][Full Text] [Related]
2. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
Dellon ES; Katzka DA; Collins MH; Hamdani M; Gupta SK; Hirano I;
Gastroenterology; 2017 Mar; 152(4):776-786.e5. PubMed ID: 27889574
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis.
Dellon ES; Katzka DA; Collins MH; Gupta SK; Lan L; Williams J; Hirano I
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):666-673.e8. PubMed ID: 29902649
[TBL] [Abstract][Full Text] [Related]
4. Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses From a 12-Week, Phase 2, Randomized, Placebo-controlled Trial.
Collins MH; Dellon ES; Katzka DA; Hirano I; Williams J; Lan L
Am J Surg Pathol; 2019 Nov; 43(11):1501-1509. PubMed ID: 31498177
[TBL] [Abstract][Full Text] [Related]
5. Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
Mukkada VA; Gupta SK; Gold BD; Dellon ES; Collins MH; Katzka DA; Falk GW; Williams J; Zhang W; Boules M; Hirano I; Desai NK
J Pediatr Gastroenterol Nutr; 2023 Dec; 77(6):760-768. PubMed ID: 37718471
[TBL] [Abstract][Full Text] [Related]
6. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Dohil R; Newbury R; Fox L; Bastian J; Aceves S
Gastroenterology; 2010 Aug; 139(2):418-29. PubMed ID: 20457157
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
Dellon ES; Woosley JT; Arrington A; McGee SJ; Covington J; Moist SE; Gebhart JH; Tylicki AE; Shoyoye SO; Martin CF; Galanko JA; Baron JA; Shaheen NJ
Gastroenterology; 2019 Jul; 157(1):65-73.e5. PubMed ID: 30872104
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.
Gupta SK; Vitanza JM; Collins MH
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):66-76.e3. PubMed ID: 24907502
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood eosinophils and other non-invasive biomarkers can monitor treatment response in eosinophilic oesophagitis.
Schlag C; Miehlke S; Heiseke A; Brockow K; Krug A; von Arnim U; Straumann A; Vieth M; Bussmann C; Mueller R; Greinwald R; Bajbouj M
Aliment Pharmacol Ther; 2015 Nov; 42(9):1122-30. PubMed ID: 26314389
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
Lucendo AJ; Miehlke S; Schlag C; Vieth M; von Arnim U; Molina-Infante J; Hartmann D; Bredenoord AJ; Ciriza de Los Rios C; Schubert S; Brückner S; Madisch A; Hayat J; Tack J; Attwood S; Mueller R; Greinwald R; Schoepfer A; Straumann A;
Gastroenterology; 2019 Jul; 157(1):74-86.e15. PubMed ID: 30922997
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension.
Dellon ES; Collins MH; Katzka DA; Mukkada VA; Falk GW; Morey R; Goodwin B; Eisner JD; Lan L; Desai NK; Williams J; Hirano I;
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1488-1498.e11. PubMed ID: 34182150
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Budesonide Oral Suspension in Children and Adolescents With Eosinophilic Esophagitis.
Gupta SK; Hill M; Vitanza JM; Farber RH; Desai NK; Williams J; Song IH
J Pediatr Gastroenterol Nutr; 2022 Aug; 75(2):186-191. PubMed ID: 35666852
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis.
Lieberman JA; Zhang J; Whitworth J; Cavender C
Ann Allergy Asthma Immunol; 2018 May; 120(5):527-531. PubMed ID: 29544738
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Epicutaneous Immunotherapy in Children With Milk-Induced Eosinophilic Esophagitis.
Spergel JM; Elci OU; Muir AB; Liacouras CA; Wilkins BJ; Burke D; Lewis MO; Brown-Whitehorn T; Cianferoni A
Clin Gastroenterol Hepatol; 2020 Feb; 18(2):328-336.e7. PubMed ID: 31100455
[TBL] [Abstract][Full Text] [Related]
16. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis.
Straumann A; Conus S; Degen L; Frei C; Bussmann C; Beglinger C; Schoepfer A; Simon HU
Clin Gastroenterol Hepatol; 2011 May; 9(5):400-9.e1. PubMed ID: 21277394
[TBL] [Abstract][Full Text] [Related]
17. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.
Hirano I; Collins MH; Katzka DA; Mukkada VA; Falk GW; Morey R; Desai NK; Lan L; Williams J; Dellon ES;
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):525-534.e10. PubMed ID: 33887475
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Pharmacologic Therapy for Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis.
Tomizawa Y; Melek J; Komaki Y; Kavitt RT; Sakuraba A
J Clin Gastroenterol; 2018 Aug; 52(7):596-606. PubMed ID: 28787360
[TBL] [Abstract][Full Text] [Related]
19. Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach.
Munoz-Persy M; Lucendo AJ
Eur J Pediatr; 2018 May; 177(5):649-663. PubMed ID: 29549437
[TBL] [Abstract][Full Text] [Related]
20. Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis.
Rothenberg ME; Dellon ES; Collins MH; Bredenoord AJ; Hirano I; Peterson KA; Brooks L; Caldwell JM; Fjällbrant H; Grindebacke H; Ho CN; Keith M; McCrae C; Sinibaldi D; White WI; Datto CJ;
N Engl J Med; 2024 Jun; 390(24):2252-2263. PubMed ID: 38924732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
